56 related articles for article (PubMed ID: 35172633)
1. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
[TBL] [Abstract][Full Text] [Related]
2. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
[TBL] [Abstract][Full Text] [Related]
3. [Strategies for liver injury caused by hepatocellular carcinoma targeted therapy].
Zhao SX; Liu SH; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1129-1132. PubMed ID: 38238944
[TBL] [Abstract][Full Text] [Related]
4. Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma.
Kim JW; Lee IJ
Clin Mol Hepatol; 2021 Jan; 27(1):103-106. PubMed ID: 33317257
[No Abstract] [Full Text] [Related]
5. [Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer].
Jia JM; Ren JS; Zhang LY
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1133-1136. PubMed ID: 38238945
[TBL] [Abstract][Full Text] [Related]
6. Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience.
Al Jarroudi O; Chaabouni H; Ulusakarya A; Almohamad W; Gumus Y; Goldschmidt E; Afqir S; Morère JF
Clin Case Rep; 2021 Apr; 9(4):2162-2167. PubMed ID: 33936657
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States.
Bteich F; Desai K; Zhang C; Kaur A; Levy RA; Bioh L; Wang A; Sultana S; Kaubisch A; Kinkhabwala M; Bellemare S; Fidvi S; Kanmaniraja D; Berkenblit R; Moon JY; Adedimeji A; Tow CY; Saenger Y
J Hepatocell Carcinoma; 2024; 11():257-269. PubMed ID: 38333221
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Lipid Metabolism Genes as Diagnostic and Prognostic Indicators in Hepatocellular Carcinoma.
Li X; Tan Y; Liu B; Guo H; Zhou Y; Yuan J; Wang F
Curr Genomics; 2023 Oct; 24(2):110-127. PubMed ID: 37994323
[TBL] [Abstract][Full Text] [Related]
9. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
Liu Y; Xu Q; Deng F; Zheng Z; Luo J; Wang P; Zhou J; Lu X; Zhang L; Chen Z; Zhang Q; Chen Q; Zuo D
J Exp Clin Cancer Res; 2023 Feb; 42(1):38. PubMed ID: 36721234
[TBL] [Abstract][Full Text] [Related]
10. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
12. PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA.
Uhlig J; Stein S; Kim HS
Future Oncol; 2022 May; 18(14):1691-1703. PubMed ID: 35172633
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
Scheiner B; Kirstein MM; Hucke F; Finkelmeier F; Schulze K; von Felden J; Koch S; Schwabl P; Hinrichs JB; Waneck F; Waidmann O; Reiberger T; Müller C; Sieghart W; Trauner M; Weinmann A; Wege H; Trojan J; Peck-Radosavljevic M; Vogel A; Pinter M
Aliment Pharmacol Ther; 2019 May; 49(10):1323-1333. PubMed ID: 30980420
[TBL] [Abstract][Full Text] [Related]
14. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
